XML 52 R27.htm IDEA: XBRL DOCUMENT
v3.23.1

Revenues (Tables) | 3 Months Ended
--- | ---
Mar. 31, 2023
Revenue from Contract with Customer [Abstract] |
Revenues by product | Revenue by product is summarized as follows:
|  | For the Three Months Ended March 31,
|  | 2023 |  | 2022
(In millions) |  | United States |  | Rest of World |  | Total |  | United States |  | Rest of World |  | Total
Multiple Sclerosis (MS): |  |  |  |  |  |  |  |  |  |  |  |
TECFIDERA |  | $ | 74.7 |  |  | $ | 199.8 |  |  | $ | 274.5 |  |  | $ | 117.1 |  |  | $ | 292.8 |  |  | $ | 409.9 |
VUMERITY |  | 93.5 |  |  | 14.7 |  |  | 108.2 |  |  | 125.2 |  |  | 2.8 |  |  | 128.0 |
Total Fumarate |  | 168.2 |  |  | 214.5 |  |  | 382.7 |  |  | 242.3 |  |  | 295.6 |  |  | 537.9 |
AVONEX |  | 102.6 |  |  | 69.8 |  |  | 172.4 |  |  | 148.0 |  |  | 81.6 |  |  | 229.6 |
PLEGRIDY |  | 29.9 |  |  | 43.3 |  |  | 73.2 |  |  | 34.3 |  |  | 45.7 |  |  | 80.0 |
Total Interferon |  | 132.5 |  |  | 113.1 |  |  | 245.6 |  |  | 182.3 |  |  | 127.3 |  |  | 309.6 |
TYSABRI |  | 245.4 |  |  | 227.4 |  |  | 472.8 |  |  | 284.5 |  |  | 236.3 |  |  | 520.8 |
FAMPYRA |  | — |  |  | 24.1 |  |  | 24.1 |  |  | — |  |  | 26.2 |  |  | 26.2 |
Subtotal: MS |  | 546.1 |  |  | 579.1 |  |  | 1,125.2 |  |  | 709.1 |  |  | 685.4 |  |  | 1,394.5 |
Spinal Muscular Atrophy: |  |  |  |  |  |  |  |  |  |  |  |
SPINRAZA |  | 146.7 |  |  | 296.6 |  |  | 443.3 |  |  | 163.3 |  |  | 309.2 |  |  | 472.5 |
Biosimilars: |  |  |  |  |  |  |  |  |  |  |  |
BENEPALI |  | — |  |  | 109.0 |  |  | 109.0 |  |  | — |  |  | 114.7 |  |  | 114.7 |
IMRALDI |  | — |  |  | 54.4 |  |  | 54.4 |  |  | — |  |  | 57.1 |  |  | 57.1 |
FLIXABI |  | — |  |  | 20.4 |  |  | 20.4 |  |  | — |  |  | 22.5 |  |  | 22.5 |
BYOOVIZ |  | 8.2 |  |  | 0.4 |  |  | 8.6 |  |  | — |  |  | — |  |  | — |
Subtotal: Biosimilars |  | 8.2 |  |  | 184.2 |  |  | 192.4 |  |  | — |  |  | 194.3 |  |  | 194.3 |
Other(1) |  | 0.4 |  |  | 2.0 |  |  | 2.4 |  |  | 2.8 |  |  | 2.2 |  |  | 5.0 |
Total product revenue |  | $ | 701.4 |  |  | $ | 1,061.9 |  |  | $ | 1,763.3 |  |  | $ | 875.2 |  |  | $ | 1,191.1 |  |  | $ | 2,066.3 |
(1) Other includes FUMADERM and ADUHELM.
Analysis of change In reserves | An analysis of the change in reserves for discounts and allowances is summarized as follows:
(In millions) |  | Discounts |  | Contractual Adjustments |  | Returns |  | Total
Balance, December 31, 2022 |  | $ | 153.8 |  |  | $ | 857.7 |  |  | $ | 23.5 |  |  | $ | 1,035.0 |
Current provisions relating to sales in current year |  | 182.3 |  |  | 638.0 |  |  | 3.5 |  |  | 823.8 |
Adjustments relating to prior years |  | (1.1) |  |  | (8.1) |  |  | 1.0 |  |  | (8.2) |
Payments/credits relating to sales in current year |  | (94.0) |  |  | (261.8) |  |  | (1.0) |  |  | (356.8) |
Payments/credits relating to sales in prior years |  | (73.3) |  |  | (368.1) |  |  | (7.4) |  |  | (448.8) |
Balance, March 31, 2023 |  | $ | 167.7 |  |  | $ | 857.7 |  |  | $ | 19.6 |  |  | $ | 1,045.0 |
Total reserves included in consolidated balance sheets | The total reserves above, which are included in our condensed consolidated balance sheets, are summarized as follows:
(In millions) |  | As of March 31, 2023 |  | As of December 31, 2022
Reduction of accounts receivable |  | $ | 137.8 |  |  | $ | 143.4 |
Component of accrued expense and other |  | 907.2 |  |  | 891.6 |
Total revenue-related reserves |  | $ | 1,045.0 |  |  | $ | 1,035.0 |
Revenues from anti-CD20 therapeutic programs | Revenue from anti-CD20 therapeutic programs is summarized in the table below. For the purposes of this footnote, we refer to RITUXAN and RITUXAN HYCELA collectively as RITUXAN.
|  | For the Three Months Ended March 31, |  |
(In millions) |  | 2023 |  | 2022 |  |  |  |
Royalty revenue on sales of OCREVUS |  | $ | 283.6 |  |  | $ | 252.3 |  |  |  |  |
Biogen’s share of pre-tax profits in the U.S. for RITUXAN, GAZYVA and LUNSUMIO |  | 112.5 |  |  | 143.2 |  |  |  |  |
Other revenue from anti-CD20 therapeutic programs |  | 3.4 |  |  | 3.9 |  |  |  |  |
Total revenue from anti-CD20 therapeutic programs |  | $ | 399.5 |  |  | $ | 399.4 |  |  |  |  |
Other revenues |
|  | For the Three Months Ended March 31, |  |
(In millions) |  | 2023 |  | 2022 |  |  |  |
Contract manufacturing revenue |  | $ | 306.9 |  |  | $ | 47.5 |  |  |  |  |
Royalty and other revenue |  | 12.2 |  |  | 18.6 |  |  |  |  |
Total contract manufacturing, royalty and other revenue |  | $ | 319.1 |  |  | $ | 66.1 |  |  |  |  |

X
- Definition Analysis of amount of and change in product revenue reserves. + References No definition available. + Details
Name: | biib_AnalysisOfAmountOfAndChangeInProductRevenueReservesTableTextBlock
Namespace Prefix: | biib_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- Definition Other revenues [Table Text Block] + References No definition available. + Details
Name: | biib_OtherrevenuesTableTextBlock
Namespace Prefix: | biib_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- Definition Revenues from anti-CD20 therapeutic programs + References No definition available. + Details
Name: | biib_RevenuesfromantiCD20therapeuticprogramsTableTextBlock
Namespace Prefix: | biib_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- Definition Summary of total product revenue reserves included in consolidated balance sheets. + References No definition available. + Details
Name: | biib_SummaryOfProductRevenueReservesIncludedInConsolidatedBalanceSheetsTableTextBlock
Namespace Prefix: | biib_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- Definition Tabular disclosure of disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor. + References Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Publisher FASB -Name Accounting Standards Codification -Topic 606 -SubTopic 10 -Section 50 -Paragraph 5 -URI https://asc.fasb.org/extlink&oid=126920106&loc=SL49130545-203045 + Details
Name: | us-gaap_DisaggregationOfRevenueTableTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- References No definition available. + Details
Name: | us-gaap_RevenueFromContractWithCustomerAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration